FDA Finalizes Guidance on Prescription Drug Use-Related Software Labeling Obligations for Sponsors

Drug sponsors and combination product developers now have a finalized regulatory framework to navigate: FDA has published its final guidance, Regulatory Considerations for Prescription Drug Use-Related Software, establishing how the Agency applies its drug labeling authorities to software outputs disseminated in connection with prescription drug products.

The guidance covers software outputs distributed by or on behalf of a drug sponsor for use with a prescription drug product or a prescription drug-led, drug-device combination product assigned to the Center for Drug Evaluation and Research (CDER) or the Center for Biologics Evaluation and Research (CBER) as the lead center. The multi-office issuance reflects the cross-functional scope: CDER, CBER, the Center for Devices and Radiological Health, the Oncology Center of Excellence, and the Office of Combination Products all contributed to the document.

For regulatory affairs leads, the practical implication centers on labeling compliance. Software outputs that meet the criteria described in the guidance are subject to FDA's existing drug labeling authorities, meaning sponsors must assess whether their digital tools, dosing calculators, companion apps, or other software disseminated alongside a prescription product fall within scope. Failure to treat qualifying outputs as labeling carries the same compliance exposure as any other mislabeling scenario under 21 CFR Part 201.

The final guidance closes the comment cycle opened by the draft issued on September 19, 2023, under docket number FDA-2023-D-2482. Sponsors who submitted comments during the draft period should review the final text for any substantive revisions to scope definitions or applicability criteria before updating their labeling control procedures. Comments on the final guidance may still be submitted at any time per 21 CFR 10.115(g)(5), online or in writing to FDA's Dockets Management office in Rockville, Maryland.

QA and regulatory teams supporting combination product programs should prioritize a gap assessment against current software documentation practices, particularly where digital outputs are already in distribution or under development for upcoming submissions.

The next measurable checkpoint for affected sponsors is aligning any pending NDA, BLA, or combination product submissions with the labeling obligations now codified in this final guidance.

Source: FDA Center for Drug Evaluation and Research via FDA.gov Guidance Documents, October 20, 2026. Docket: FDA-2023-D-2482.